.abstract img { width:300px !important; height:auto; display:block; text-align:center; margin-top:10px } .abstract { overflow-x:scroll } .abstract table { width:100%; display:block; border:hidden; border-collapse: collapse; margin-top:10px } .abstract td, th { border-top: 1px solid #ddd; padding: 4px 8px; } .abstract tbody tr:nth-child(even) td { background-color: #efefef; } .abstract a { overflow-wrap: break-word; word-wrap: break-word; }
A5107 - High-Flow Oxygen in Patients with Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Author Block: A. Salé1, S. Marchand Adam2, M. Le Garrec3, M. Kerjouan3, P. Diot2, S. Jouneau3; 1CHU RENNES, Rennes, France, 2CHRU TOURS, TOURS CEDEX 9, France, 3CHU RENNES, RENNES, France.
Introduction Acute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF) is a life threatening complication usually associated with patient’s hospitalization due to severe acute respiratory failure. Beside etiological treatment, such as antibiotics or corticosteroids, management of hypoxemia is a major challenge. The development of high-flow humidified oxygenation (HFO) via specific nasal cannula offers improvement in intensive care unit patients but has not been evaluated in patients with AEIPF. Methods In a bi-centric prospective observational study we recruited 9 patients with AEIPF and compared oxygenation via facial mask followed by HFO. Results First we could figure out that patients, families, physicians and nurses preferred oxygenation with HFO rather than standard facial mask. Secondly, we have shown that respiratory rate (33 vs 24/min, p=0.0078) decreased significantly after 1 hour with HFO compared to facial mask as well as anxiety and discomfort. Eventually, the evolution was fatal with most patients deceasing within 10 days. Conclusion HFO could be a symptomatic treatment of acute respiratory failure in patients with AEIPF. Larger studies are needed to assess the proper place HFO in the armamentarium of treatment for AEIPF.